Back when the patent war was brewing over CRISPR/Cas9, the Broad Institute's Feng Zhang made it clear that he believed the big innovations in gene editing still lay ahead. And in the last few days he set out to prove he was right, pointing to an alternative to Cas9 that could wind up serving as a much better tool to use to perform surgery on a gene.
A two-drug combo that matches Afinitor with an experimental compound proved effective in killing pancreatic cancer cells and blunting tumor growth in cell lines and mouse models for the lethal disease. Investigators at the University of Florida combined Afinitor with a synthetic compound coded PF-04554787. They targeted a protein known as focal adhesion kinase, or FAK, which triggers an enzyme called AKT, which in turn assist in the survival of islet cells in the pancreas. When islet cells start turning into tumors, the FAK protein is overproduced, helping pancreatic neuroendocrine tumors to resist chemo. Read more >>
Investigators at the Salk Institute have blazed a new trail branching out from the closely studied mGluR5 pathway in the brain, and they say it could ultimately lead to new therapies to treat neurodevelopmental disorders like autism and schizophrenia. Read more >>
POPULAR COMMENT THREADS
Matthew Shair, a professor of chemistry and chemical biology at Harvard, and his team have isolated and synthesized a molecule from sea sponges that prevents cancerous growth.
Investigators at NIH's National Institute of Allergy and Infectious Diseases have come up with new evidence to ID a key culprit involved in the death of neurons and the development of neurodegenerative diseases like Alzheimer's.
Investigators at the Perelman School of Medicine at the University of Pennsylvania. say they have reached some new insights into the structure of a protein complex that is a root cause of a clotting disorder (heparin-induced thrombocytopenia) that strikes patients who receive the anti-clotting drug heparin.
One of the best known theories as to why people develop Alzheimer's is that toxic clusters of amyloid beta in the brain wipe out memories and trigger dementia in the elderly. Now researchers say that they have determined that the IL1RAP immune pathway could provide a promising avenue for drug developers.
A study recently published in the Journal of Neuroscience shows a histone deacetylase inhibitor (HDACi)--RGFP966--can rescue the ability to form new memories, a well-known feature to go awry in Alzheimer's disease.
Scientists at UC Santa Cruz have identified a key structural component of the telomerase enzyme that can contribute to cell proliferation in cancer cells, publishing their findings in Nature Structural and Molecular Biology. And they say that the work could help pave the way to a new, targeted cancer treatment that zeroes in on telomerase.
From Our Sister Sites
Two weeks after Verastem was forced to acknowledge that its lead cancer drug had flopped badly in a clinical study for mesothelioma, founder and Executive Chairman Christoph Westphal has brought out...
Roche's much-hyped multiple sclerosis treatment ocrelizumab kept up its momentum with the release of detailed late-stage data, burnishing hopes the injected drug is a blockbuster in the making.